Drugs / PCV13-TT
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05934890 | Nov 2023 → Mar 2025 overdue | pneumococcal infection | Walvax Biotechnology Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCV13-TT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05934890 ↗ |
| Modality | Vaccine | “novel 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13-TT)” NCT05934890 ↗ |
| Route | Intramuscular | “0.5 mL suspension for intramuscular injection” NCT05934890 ↗ |